nct_id: NCT04728893
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2021-01-28'
study_start_date: '2021-04-05'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Nemtabrutinib'
long_title: A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants
  With Hematologic Malignancies
last_updated: '2025-11-10'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE2
principal_investigator: NA
principal_investigator_institution: Merck Sharp & Dohme LLC
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 490
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  within 7 days before C1D1 (the first dose of study treatment)'
- '* Has a life expectancy of at least 3 months, based on the investigator assessment'
- '* Has the ability to swallow and retain oral medication'
- '* Participants who are Hepatitis B surface antigen (HBsAg)-positive are eligible
  if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks
  and have undetectable HBV viral load prior to randomization'
- '* Participants with history of Hepatitis C virus (HCV) infection are eligible if
  HCV viral load is undetectable at screening'
- '* Has adequate organ function'
- '* Male participants agree to refrain from donating sperm and agree to either remain
  abstinent from penile-vaginal intercourse as their preferred and usual lifestyle
  OR agree to use contraception, during the intervention period and for at least the
  time required to eliminate the study intervention after last dose of study intervention'
- '* Female participants assigned female sex at birth who are not pregnant or breastfeeding
  are eligible to participate if not a participant of childbearing potential (POCBP),
  or if a POCBP they either use a contraceptive method that is highly effective OR
  remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle
  during the intervention period and for at least to eliminate study intervention
  after the last dose of study intervention'
- '* Participants with Human immunodeficiency virus (HIV) are eligible if they meet
  all of the following: the CD4 count is \>350 cells/uL at screening, the HIV viral
  load is below the detectable level, are on a stable ART regimen for at least 4 weeks
  prior to study entry, and are compliant with their ART'
- Part 1 and Part 2 (Cohorts A to C and J)
- '* Has a confirmed diagnosis of Chronic lymphocytic leukemia/ Small lymphocytic
  lymphoma (CLL/SLL) with'
- '* At least 2 lines of prior therapy (Part 1 only)'
- '* Part 2 Cohort A: CLL/SLL participants who are relapsed or refractory to prior
  therapy with a covalent, irreversible Bruton''s tyrosine kinase inhibitor (BTKi),
  and a B-cell lymphoma 2 inhibitor (BCL2i). CLL participants must have received and
  failed, been intolerant to, or determined by their treating physician to be a poor
  phosphoinositide 3-kinase inhibitor (PI3Ki) candidate or ineligible for a PI3Ki
  per local guidelines'
- '* Part 2 Cohort B: CLL/SLL participants who are relapsed or refractory following
  at least 1 line of prior therapy and are BTKi treatment naive'
- '* Part 2 Cohort C: CLL/SLL participants with 17p deletion or tumor protein p53
  (TP53) mutation who are relapsed or refractory following at least 1 line of prior
  therapy'
- '* Part 2 Cohort J: CLL/SLL participants whose disease relapsed or was refractory
  to prior therapy with a covalent/irreversible BTKi and BCL2i. NOTE: As of Protocol
  Amendment 09, at least 10 CLL/SLL participants whose disease relapsed or was refractory
  to prior therapy with a covalent/irreversible BTKi, BCL2i and noncovalent/reversible
  BTKi (all three classes of therapies are required) will be enrolled into Cohort
  J'
- '* Has active disease for CLL/SLL clearly documented to initiate therapy'
- '* For SLL participants in Part 2: Has evaluable core or excisional lymph node biopsy
  for biomarker analysis from an archival or newly obtained biopsy or bone marrow
  aspirate at Screening (optional for participants enrolling in Part 1)'
- Part 2 (Cohorts D to G)
- '\- Has a confirmed diagnosis of and meets the following prior therapy requirements:'
- '* Participants with Richter''s transformation who are relapsed or refractory following
  at least 1 line of prior therapy (Cohort D)'
- '* Participants with pathologically confirmed Mantle-cell lymphoma (MCL), documented
  by either overexpression of cyclin D1 or t (11;14), who are relapsed or are refractory
  to chemoimmunotherapy and a covalent irreversible BTKi (Cohort E)'
- '* Participants with Marginal zone lymphoma (MZL) (including splenic, nodal, and
  extra nodal MZL) who are relapsed or refractory to at least one prior line of systemic
  therapy including an anti-CD20-based regimen'
- '* Participants with Follicular lymphoma (FL) who are relapsed or refractory to
  chemoimmunotherapy and immunomodulatory agents (such as lenalidomide based regimen)
  (Cohort G)'
- '* Have measurable disease defined as at least 1 lesion that can be accurately measured
  in at least 2 dimensions with spiral Computed tomography (CT) scan'
- '* Has a lymph node biopsy for biomarker analysis from an archival or newly obtained
  biopsy or bone marrow aspirate (Cohort D) at Screening'
- "Part 2 (Cohort H): confirmed diagnosis of Waldenstr\xF6m's macroglobulinemia (WM);\
  \ participants who are relapsed or refractory to standard therapies for WM including\
  \ chemoimmunotherapy and a covalent irreversible BTKi"
- '* Has active disease defined as 1 of the following: systemic symptoms, physical
  findings, laboratory abnormalities, coexisting disease'
- "* Has measurable disease, satisfying any of the following: at least 1 lesion that\
  \ can be accurately measured in at least 2 dimensions with spiral CT scan (minimum\
  \ measurement must be \\>15 mm in the longest diameter or \\>10 mm in the short\
  \ axis); IgM \u2265450 mg/dL; or bone marrow infiltration of 10%"
- '* Has fresh bone marrow aspirate or a lymph node biopsy for biomarker analysis
  at Screening or a lymph node biopsy from an archival'
- 'Exclude - Exclusion Criteria:'
- Exclude - * Has active HBV/HCV infection (Part 1 and Part 2)
- "Exclude - * Has a history of malignancy \u22643 years before providing documented\
  \ informed consent. Participants with basal cell carcinoma of skin, squamous cell\
  \ carcinoma of skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer\
  \ in situ) that have undergone potential curative therapy are not excluded. Participants\
  \ with low-risk, early-stage prostate cancer (T1-T2a, Gleason score \u22646, and\
  \ prostate-specific antigen \\<10 ng/mL) either treated with definitive intent or\
  \ untreated in active surveillance with SD are not excluded"
- Exclude - * Has active central nervous system (CNS) disease
- Exclude - * Has an active infection requiring systemic therapy
- Exclude - * Has received prior systemic anti-cancer therapy within 5 half-lives
  or 4 weeks (if prior therapy was a monoclonal antibody) before C1D1
- Exclude - * Is currently participating in or has participated in a study of an investigational
  agent or has used an investigational device within 4 weeks prior to the first dose
  of study intervention
- Exclude - * Has any clinically significant gastrointestinal abnormalities that might
  alter absorption
- Exclude - * History of severe bleeding disorders
short_title: Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic
  Malignancies (MK-1026-003)
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Merck Sharp & Dohme LLC
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: "The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib\
  \ (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic\
  \ leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal\
  \ zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and\
  \ Waldenstr\xF6m's macroglobulinemia (WM)."
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Nemtabrutinib
      arm_internal_id: 0
      arm_description: Participants receive nemtabrutinib orally once daily (QD) until
        progressive disease (PD) or discontinuation.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Nemtabrutinib'
        level_internal_id: 0
        level_suspended: N
    match:
    - and:
      - clinical:
          age_numerical: '>=18'
          disease_status:
          - Recurrent
          - Refractory
          oncotree_primary_diagnosis: Lymphoid Neoplasm
      - or:
        - genomic:
            hugo_symbol: TP53
            variant_category: Mutation
        - genomic:
          hugo_symbol: TP53
          variant_category: Copy Number Variation

